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Abstract 
 
 ING1 (Inhibitor of Growth 1) was identified and characterized as a “candidate” tumor 
suppressor gene in 1996. Subsequently four more genes, also characterized as “candidate” 
tumor suppressor genes, were identified by homology search: ING2, ING3, ING4 and ING5. 
The ING proteins are characterized by a high homology in their C-terminal domain which 
contains a Nuclear Localization Sequence (NLS) and a Plant HomeoDomain (PHD) which 
has a high affinity to Histone 3 tri-methylated on lysine 4 (H3K4Me3). The ING proteins 
have been involved in the control of cell growth, senescence, apoptosis, chromatin 
remodelling and DNA repair. Within the ING family, ING1 and ING2 form a subgroup since 
they are evolutionarily and functionally close. In Yeast, only one gene, Pho23, is related to 
ING1 and ING2 and possesses also a PHD. Recently, the ING1 and ING2 tumor suppressor 
status has been fully established since several studies have described the loss of ING1 and 
ING2 protein expression in human tumors and both ING1 and ING2 knockout mice were 
reported to have spontaneously developed tumors, B-cell lymphomas and soft tissue sarcomas 
respectively. In this review we will describe for the first time what is known about ING1 and 
ING2 genes, proteins, their regulations in both human and mice, and their status in human 
tumors. Furthermore, we explore the current knowledge about identified functions involving 
ING1 and ING2 in tumor suppression pathways especially in the control of cell cycle and in 
genome stability. 
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Introduction 
 
 A tumor suppressor gene (TSG) encodes for a protein which blocks tumor 
development. These genes negatively regulate cell proliferation and/or contribute to the 
maintenance of genome stability. Their loss contributes to malignant transformation. They are 
divided in two classes. Type I TSGs or “caretakers” are directly involved in the maintenance 
of DNA integrity through DNA repair pathways (e.g.: BRCA1/2, MSH2, etc.); whereas, type 
II TSGs or “gatekeepers” control cell cycle, senescence, apoptosis, autophagy and suppress 
angiogenesis and cell invasion (e.g.: p53, pRb, etc.) [1,2]. 
 In 1996, Karl Riabowol’s group identified ING1 (Inhibitor of Growth 1) from an in 
vivo screen which aimed at isolating new candidate TSG [3]. Following ING1 discovery, four 
genes having a high homology to ING1 were identified as candidate TSG and were named 
ING2-ING5 [4-7]. Subsequently, three ING genes were identified in Saccharomyces 
cerevisiae: Yng1, Yng2 and Pho23 and two in Saccharomyces pombe: Png1 and Png2 [8]. 
Yeast ING proteins share a significant identity of 50 to 60% with the C-terminal region of 
human ING1 [8]. Since then, ING proteins were also identified in many other species 
including frog, fish, mosquito, fruit fly, worm, xenopus and plant. The ING proteins are 
characterized by their C-terminal region which is highly conserved from human to plant and 
contains a Plant HomeoDomain (PHD) [9-11]. In addition, the C-terminus contains a Nuclear 
Localisation Signal (NLS) which targets INGs to the nucleus [9]. ING proteins possess also a 
strongly conserved region that has not yet been described in any other protein and thus has 
been named the Novel Conserved Region (NCR). The N-terminal domain is unique to each 
ING [9]. Thus, ING proteins are highly conserved during evolution which suggests their 
involvement in important biological processes [9,12]. Accordingly, functional studies have 
characterised ING proteins as “candidate” tumor suppressor proteins that are involved in 
many processes like cell growth, apoptosis, senescence, migration and DNA repair. 
Furthermore, many studies have shown that these genes are lost or misregulated in several 
tumour types [13]. Within the ING family, ING1 and ING2 form a subgroup since they are 
evolutionarily and functionally close [9]. Recently, both ING1 and ING2 knockout mice were 
reported to spontaneously develop tumors with a high frequency [14-17]. 
 In this review we will detail for the first time what is known about ING1 and ING2 
gene, protein, their regulations in both human and mice, and their status in human tumors. 
Furthermore, we discuss the involvement of ING1 and ING2 functions in tumor suppression 
especially in the control of cell cycle and genome stability. 
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ING1 and ING2 genes and proteins: structure and regulations 
 
Human ING1 and ING2 are located close to chromosome telomere 
 
 Human ING1 and ING2 are located on two different chromosomes. Human ING1 has 
been mapped at chromosome 13q34 and human ING2 at chromosome 4q35.1. Interestingly, 
both are located close to the telomeric region [4,6,9] (Fig.1, S1). The amino acid sequence of 
human ING2 displays 70% homology with ING1 sequence [4] (Fig.2). The subtelomeric 
location of human ING1 and ING2 genes and their high homology suggest that ING1 and 
ING2 could result from the duplication of these regions from a common ancestor [9]. In 
contrast, mouse ING1 and ING2 are located on the same chromosome. ING1 has been 
mapped on chromosome 8 A1.1 and ING2 on chromosome 8 B2 [18] (Fig.S1). Phylogenetic 
tree analysis has revealed that human and mouse ING1 from one part and human and mouse 
ING2 from another part belong to the same group of related sequences [9] (Fig.S2). 
 
 
ING1 structure and transcriptional regulation 
 
 Human ING1 is made of four exons, exon 1a, 1b, 1c, and 2, resulting in five 
transcribed isoforms (ING1a, ING1b, ING1c, and ING1d) (Fig1, S1). They are the result of 
different promoters and alternative splicing. ING1 is ubiquitously expressed in tissues. ING1b 
is the most abundant form among ING1 isoforms (Fig1) (Fig.1 represents a scheme of ING1b 
isoform and of ING2a and ING2b. ING2 proteins are more detailed than ING1 proteins 
because the ING1 isoforms have already been published [13] and because ING2b has never 
been included in a scheme describing ING2 proteins since its identification. A detailed 
scheme of ING1 isoforms is represented on Fig.S1). 
 However, their expression can vary greatly e.g. human ING1a mRNA expression is 
highly expressed in testis; whereas, human ING1b mRNA is highly expressed in thymus, 
spleen and brain and human ING1c mRNA is highly expressed in thymus and human ING1d 
is highly expressed in lung, liver, kidney, thymus and small intestine [19]. In contrast, mouse 
ING1 consists of four exons, exon 1a, 1b, 1c and 2, resulting in three transcribed isoforms 
(ING1a, ING1b and ING1c) (Fig.S1) [18]. 
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 In addition, human ING1 transcriptional regulation remains unknown but need to be 
explored since ING1 mRNA expression is frequently lost in human tumors (see thereafter). 
The expression of murine ING1 has been reported to be independent of p53 [20]. 
 
 
ING2 structure and transcriptional regulation 
 
 ING2 is made up of three exons, exon 1a, 1b and 2, resulting in two transcribed 
isoforms: ING2a and ING2b [4,6,21] (Fig.1). They are the result of an alternative splicing 
between exons 1a and 1b. Both ING2a and ING2b mRNA are ubiquitously expressed. 
However, the level of ING2b mRNA transcript expression is much lower. Furthermore, whilst 
ING2b mRNA expression has been shown at the RNA level, no protein has ever been 
detected [21,19]. By which mechanism ING2b expression may be regulated at the RNA level 
remains unknown. ING2 mouse gene is also comprised of three exons giving two transcribed 
isoforms by alternative splicing: ING2a and ING2b [21] (Fig.S1). Human and mouse ING2a 
cDNAs share 90% identity whilst human and mouse ING2b cDNAs share 75% identity (Fig. 
S2A).  
 ING2 promoter displays regulatory elements that control its transcription. ING2a 
promoter possesses two p53 binding sites and indeed p53 activation by Nutlin-3 has been 
shown to repress ING2a transcription [22]. ING2a expression is also regulated by NF-B as 
its promoter possesses one NF-B binding site. Thus, in colon cancer, ING2a expression is 
enhanced through NF-B activation [23]. So far, no transcriptional regulatory element has 
been established for ING2b. However, a putative Heat Shock transcription Factor 1 and 2 
binding site, a C-Rel binding site, a SP1 binding site, five Myeloid Zinc Finger 1 binding sites 
and a p300 binding site are predicted on ING2b promoter [21]. Complementary studies about 
ING2 transcriptional regulation would allow a better understanding of ING2 functions since 
misregulation of these transcription factors could alter ING2 expression. Interestingly, 
through still unknown mechanisms, downregulation of ING2a results in changes in ING2b 
mRNA expression. Conversely, downregulation of ING2b also triggers changes in ING2a 
mRNA expression [21]. This raises the possibility of interplay between ING2a and ING2b 
mRNA expression. Consequently, the analysis of the expression of both ING2a and ING2b 
mRNAs would be of interest to better characterize the status of ING2 in human tumors. 
 ING2 expression is regulated by tissues-dependent mechanisms since ING2a is highly 
expressed in the skeletal muscle, lung, thymus and the in pancreas [19,21]. Interestingly, 
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ING2 has been involved in muscle differentiation by regulating myogenin transcription [24]. 
Moreover, both ING2a and ING2b are especially highly expressed in human and mouse testis 
[17,21]. Indeed it has been shown that ING2 plays a role in male fertility [17]. It suggests that 
ING2 may also play a role in the physiology of the lung, thymus and pancreas. 
 
 
ING1 and ING2 proteins structure 
 
 Human ING1a and ING1b are the most abundant ING1 isoforms. No information has 
currently been published regarding functions of the others. Human ING1a and ING1b have 
respectively a molecular weight of 47 kDa and 33 kDa (Fig1, 2, S1). Amino acid sequence 
alignment of human ING1 versus mouse ING1 isoforms has revealed a high similarity 
between mouse ING1b and human ING1b since they share 89% identity (Fig.S2). Mouse 
ING1b has a molecular weight of 37kDa and possesses the same domains than human ING1b. 
The alternative splicing between mouse ING1a, ING1b and ING1c results in the absence of 
the PCNA-interacting protein (PIP) and Partial Bromo Domain (PBD) domains on ING1a and 
ING1c. Consequently, ING1a and ING1c have a predicted molecular weight of 31 kDa [18] 
(FigS1, 2). Thus, there is no equivalent to human ING1a in mice. Anyway, human and mouse 
ING1b have a high homology. Consequently, mouse models are pertinent for ING1b in vivo 
studies (Fig.S1, S2). 
 Human ING2a has a molecular weight of 33 kDa whilst ING2b has a predicted 
molecular weight of 28 kDa. However, ING2b protein has never been experimentally detected 
[4,6,21]. The alternative splicing between human ING2a and ING2b results in the absence of 
the Leucine Zipper Like (LZL) domain on ING2b (Fig.1C). Human and mouse ING2a 
proteins are very close as they differ by only ten amino acids distributed across the length of 
the protein and are made of the same protein domains (Fig.S2B). Moreover, mouse ING2a has 
the same molecular weight as human ING2a. On the other hand, mouse ING2b is smaller than 
human ING2b and has a predicted molecular weight of 20,3 kDa since mouse ING2b is also 
truncated of some part of its NCR domain [21] (Fig.1, S1). Overall, human and mouse ING2a 
and ING2b have a high homology. Consequently, mouse models are pertinent for ING2 in 
vivo studies (Fig.S1, S2). 
 ING1 and ING2 C-terminal domain contain a PHD with a zinc binding motif 
described as a domain having a high affinity for the histone 3 tri-methylated on lysine 4  
(H3K4Me3) [9,10,25-30] (Fig.1, S1). ING1 and ING2 also have a PolyBasic Region (PBR) 
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adjacent to the PHD [9] (Fig.2). As its closest paralog to ING1, ING2 also contains a amino 
acids motif in its C-terminal part. The REASP amino acids motif has been described as a 14-
3-3 binding motif containing a phosphoserine [31]. ING1, phosphorylated on its serine 199, 
interacts with the 14-3-3 protein through its REASP motif to be shuttled from the nucleus to 
the cytoplasm [9,32]. In the cytoplasm, ING1 is dephosphorylated and interacts with 
karyopherines 2 and 1 through this region to allow its import to the nucleus [33]. One can 
hypothesize that ING2 is also phosphorylated on its serine located inside the REASP motif 
and that ING2 may also interacts with the 14-3-3 and with karyopherines 2 and 1 through 
its REASP motif [9] (Fig.2). ING1 and ING2 C-terminal domains also contain a NLS which 
possesses three Nucleolar Targeting Sequences (NTS), to be targeted to the nucleolus [21,34] 
(Fig.1, 2). ING1 and ING2 proteins are characterized by a NCR in their N-terminal part [9] 
(Fig.1, S1). NCR domain has been suggested to be necessary for the binding between ING1 
and histone acetyltransferase (HAT) or histone deacetylase (HDAC) [28]. This domain was 
also subsequently named Lamin Interaction Domain (LID) because ING1, as well as ING2, 
ING3 and ING4, coprecipitates with Lamin A through this domain. It has been shown that the 
binding of ING1 to Lamin A through the ING1 LID regulates ING1 protein level and ING1 
nuclear localisation [35]. It is thus possible that the ING2 LID could have a similar function. 
 The N-terminus is unique to each ING protein. ING1b N-terminus possesses a PIP 
domain. Among the ING1 proteins this domain is only restricted to ING1b isoform. ING1b 
PIP domain has been shown to interact with PCNA [34] (Fig.1, 2, S1). A PBD is also present 
close to the PIP on ING1b [36,37]. As mentioned previously, ING2a N-terminus also contains 
a LZL motif. This motif contains leucine residues spanning every seven amino acids and 
forming a hydrophobic patch. This LZL could present a leucine zipper coiled-coil 
conformation. Such conformation could allow the interaction with other leucine zipper–
containing proteins [9]. Indeed, ING4 also contains a LZL domain and its homodimerisation 
has recently been demonstrated by cristallography [38,39]. Subsequently, putative 
homodimers have also been predicted for the others INGs, including ING2 [38]. Nevertheless, 
this hypothesis remains to be tested for ING2. 
 So far, only a few studies have investigated ING1 and ING2 protein regulation. 
Nonetheless, in response to genotoxic stress, human ING1b has been described to be 
phosphorylated on its serine 126 by the kinases Cdk1 or Chk1. This phosphorylation promote 
its protein stability [40]. In addition, another study has reported that ING1b can be degraded 
through the 20S proteasome complex. The NAD(P)H quinone oxidoreductase has been 
described to inhibit this degradation when ING1b is phosphorylated on its serine 126 [41]. 
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Moreover, human ING2a protein level has been shown to be regulated by ubiquitylation. A 
member of the E6AP carboxyl terminus ubiquitin ligases (HECT) family named SMURF1 
(Smad Ubiquitination Regulating Factor 1) interacts with ING2, inducing ING2 
polyubiquitylation and its proteasomal degradation. ING2a interacts with SMURF1 through 
its central region corresponding to the NCR and the NLS domains while its PHD is the 
domain targeted by ubiquitinylation [42]. This degradation could play a more important role 
in the pancreas and testis where both ING2a and SMURF1 are highly expressed 
[19,21,43,44]. Moreover, SMURF1 expression is amplified in pancreatic cancer [44]. Thus, it 
could be interesting to analyze whether ING2a protein expression is reduced in pancreatic 
cancer because of an enhancement of its degradation by an increased SMURF1 
ubiquitinylation. 
 
 
ING1 and ING2 status in human tumors 
 
 Most studies have described that ING1 and ING2 expression is decreased or lost in 
human tumors which argues for a role for ING1 and ING2 as a tumor suppressor gene [13]. 
 A high frequency of loss of heterozygosity (LOH) of the ING1 chromosomal region 
13q34 has been found in head and neck carcinomas and in esophageal squamous cell 
carcinomas [45-47]. Expression of ING1 is frequently lost in breast cancer tumors [13,48,49]. 
Most of the time, ING1 expression is lost at the RNA level. ING1 mRNA status has been 
studied using primers targeting exon E2 corresponding to all ING1 isoforms or targeting exon 
E1a corresponding to ING1b mRNA (Fig.1, S1). Consequently, there is currently no data 
available regarding ING1a, ING1c or ING1d status in human tumors [13]. Less frequently, 
some mutations have been found on ING1 gene. These mutations occur in the PHD [13,50]. 
They thus could decrease ING1 binding to H3K4Me3 [29] (see thereafter). Moreover, in 
breast cancer and neuroblastoma, ING1 loss has been associated with more differentiated 
tumors suggesting that ING1 loss is associated with poor prognosis [13,51,52]. In addition, in 
oral carcinomas, ING1 loss results in a shift of the protein localization from the nucleus to the 
cytoplasm resulting in the loss of its nuclear functions [13,53]. 
 In the case of ING2, a high frequency of LOH of the ING2 chromosomal region 4q32-
35.1 has been found in basal cell carcinomas, in head and neck squamous cell carcinomas and 
in hepatocellular carcinomas [54-56]. ING2 LOH is associated with advanced tumor stage in 
head and neck squamous cell carcinomas [54]. Strikingly, no report has shown the presence of 
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ING2 mutation in human tumors. But, several studies have described that ING2 is lost at the 
RNA level. Indeed, ING2 RNA expression is reduced in breast and ovarian cancers, in 
hepatocellular carcinomas and in non-small cell lung carcinomas [19,45,53,57]. In melanoma, 
loss of ING2 nuclear expression has been reported but it remains to be investigated if this is 
due to a loss of ING2 mRNA expression [58]. In addition, no shift of the protein localization 
has been reported for ING2 but it remains possible since it has been described for ING1 and 
for other INGs [13,53]. 
 Contrary to its status observed in many tumors ING1b mRNA has been once shown to 
be overexpressed in brain tumor. It has been associated with a mutation within the NLS. Since 
this mutation was located within a consensus phosphorylation site (serine 81), it has been 
suggested that ING1b overexpression may be due to a disregulation of a post-translationnal 
modification [59]. Moreover, in contrast to its status observed in many tumors Kumamoto and 
coll., have shown in colon cancer that ING2 mRNA expression is upregulated and may 
enhance tumor invasion by enhancing Matrix Metallo Proteinase 13 expression. NF-B 
activation was suggested as a possible mechanism to upregulate ING2a mRNA [23]. 
However, it remains unclear how and why ING2 is upregulated in colon cancer. These studies 
raise a new assumption where ING1b or ING2a could have under certain conditions a role as 
an oncogene. This is not restricted to ING1b or ING2a since other TSGs such as E2F1 which 
regulates cell death through activation of p53 and p73 pathways have also been described to 
support tumor cell migration and invasion when it is overexpressed, giving it oncogenic 
properties [60]. 
 In some cancers, such as in breast and lung cancers, ING1b and ING2a expression 
decrease could be involved in the tumor initiation and/or progression [13,45,53,49,58] since 
ING1b and ING2a mRNA loss of expression occurs at an early stage of tumor development. 
Loss of ING1b or ING2a mRNA could be the result of either misregulation of transcription 
factors that regulate ING1 or ING2 expression or gene inactivation mechanisms such as 
epigenetic mechanisms including DNA methylation and histone modifications. These losses 
could also result from misregulation of microRNAs targeting ING1b or ING2a mRNA since 
in gastric cancer miR-622 have been described to decrease the ING1 mRNA expression by 
targeting the ING1 3’UTR [61]. 
 
 
ING1 and ING2 knockout mice 
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 Development of ING1 and ING2 knockout mice are an interesting in vivo model to 
study the physiological role of ING1 and ING2 since both have been reported to be lost in 
human tumors. Moreover, human and mouse ING1b or human and mouse ING2a are highly 
homologous (Fig.S2).  
 Two models of ING1 knockout mice have been developed. The first one was 
developed by removing the common exon E2 shared by the three ING1 mouse isoforms 
(Fig.S1). Thus it results in the absence of the three isoforms (Fig.S1). This model displays an 
increased incidence of spontaneous tumors with mostly B-cell lymphoma from germinal 
center origin [14,15]. They also exhibit a decrease in term of survival in response to six daily 
doses of 2.3 Gy of -rays compared to the wild type mice which suggests a role for ING1 in 
DNA repair [14] (see thereafter). In the second model only mouse ING1b has been 
inactivated. ING1b-/- mice develop B-cell lymphoma from germinal center origin with a high 
incidence [14-16]. Strikingly, these ING1b-/- mice have a tumor spectrum slightly different 
than ING1-/- mice suggesting a role for mouse ING1a and mouse ING1c isoforms by 
modulating mouse ING1b activity to prevent tumorigenesis. These two models of ING1 
knockout mice have demonstrated that ING1 functions are independent of p53. Interestingly, 
p53-/- ING1b-/- mice develop, with an incidence of 63%, aggressive diffuse large lymphomas 
(DLBCL) whereas p53-/- mice develop T-cell lymphomas with an incidence of 60%. In 
addition, expression analysis of Bax in the thymus, spleen, liver and brain have been 
performed in these mouse models in response to ionizing radiations. It appears that for all 
these tissues, Bax expression is highly induced in ING1b-/- mice and slightly less in ING1b -
/- p53 -/- mice whereas it is not expressed in p53-/- mice [15], suggesting that ING1 induces 
Bax expression and consequently apoptosis independently of p53. Thus, because of their 
different tumor spectrum, ING1 has p53-dependent and independent functions. Moreover, it 
seems that they cooperate to suppress DLBCL [16].  
 Then, a model of knockout mice targeting both ING2a and ING2b isoforms has been 
engineered. Saito and coll. have reported that ING2-/- mice develop soft-tissue sarcomas with 
an incidence of 46%, and most frequently histiocytic sarcomas (28%) [17]. A particular 
phenotypic trait was observed in ING2-/- male mice. These mice were infertile. They showed 
deficient spermatogenesis, small testes, seminiferous tubules degeneration, abnormal 
spermatozoa motility and morphology from the age of eight weeks. Analysis of testes DNA 
content showed that ING2-/- testis cells failed to complete meiosis II and have an altered 
meiotic recombination. RNA microarray profiling showed a deregulation of genes specifically 
expressed in spermatid and spermatozoa suggesting that ING2 could have an effect in 
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spermatids and spermatozoa differentiation. Moreover, comparisons of public microarray 
datasets revealed an association between ING2 deficiency and human male infertility. 
Consequently, this opens new prospects for a role of ING2 in male meiosis [17]. 
 Since previous reports have suggested a functional interaction between ING2a and p53 
[4], the effect of ING2 knockout on p53-dependent and independent apoptosis was also 
investigated. ING2-/- germinal cells undergo more apoptosis than the WT and their p53 
protein level is increased. It could be the result of testicular degeneration in the absence of 
ING2 or of novel regulatory interactions between ING2 and p53. In the aim to determine p53-
independent apoptosis in ING2-/- testes, double knockout ING2 and p53 mice were 
generated. p53-/- mice do not show spermatogenesis defect and are fertile. ING2 deficiency in 
p53-/- background presents the same abnormalities in term of spermatogenesis deficiency 
than ING2-/- mice. However, these abnormalities were less severe than those in ING2-/- 
mice. Thus, simultaneous loss of ING2 and p53 partially abrogates the apoptosis observed in 
ING2-/- testes. This suggests that ING2 deficiency in testis induces both p53-dependent and 
independent apoptosis [17]. These double knockout ING2 and p53 mice should also provide 
clues on dependent and independent effects of p53 and ING2 in tumor suppression. 
 Surprisingly, although ING1 and ING2 have a high homology, a different phenotype 
has been observed in between these knockout mice models. In human, ING1 and ING2 status 
have never been fully investigated in B-cell lymphomas and histiocytic sarcomas. Such 
studies would allow the correlation with the phenotypes observed in mouse knockout models. 
Double knockout mice for ING1 and ING2 have not been engineered yet. This model will 
provide clues regarding the potentially redundant functions between ING1 and ING2. 
 
 
Tumor suppressor functions for ING1 and ING2 
 
 Since their identification, ING1b and ING2a functions have been investigated using 
mostly overexpression strategies in human cell lines. More recently, downregulation of 
ING1b and ING2a, as it occurs in human tumors has given new insight in the understanding 
of ING1b and ING2a functions. In this part, we will discuss which ING1b and ING2a 
functions define them as a tumor suppressor genes and how their loss could contribute to 
tumor development. Some functions characterize ING1b and ING2a as gatekeepers and others 
as caretakers. 
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ING1 gatekeeper functions regulate cell cycle, senescence and apoptosis 
 
 Among ING1 isoforms human ING1b is the most abundant form. Its functions have 
been well defined since its identification. Thanks to these studies its status as a tumor 
suppressor has been fully established. In contrast, human ING1a is less expressed and less 
studied. Its TSG status is not as well defined since ING1a has just been involved in 
senescence. So far, there is no study reporting any function for the other ING1 isoforms. 
 
 
ING1 controls gene transcription 
 
 Initially, ING1 has been described to interact with the mSin3a/HDAC1-2/Sap30 
complex [28,30]. Then, studies of ING2 PHD (see thereafter) have revealed that ING2 PHD 
and of ING1 PHD have a high affinity with H3K4Me3 [26,27]. Subsequently, the interaction 
of ING1 PHD has been better characterized. ING1 PHD interacts strongly with H3K4Me3 
and more weakly with H3K4Me2 and H3K4Me1 [29]. Recognition of H3K4Me3 by ING1 
PHD has been described to promote ING1 functions such as DNA repair and apoptosis [29]. 
Trimethylated histone is mainly found on transcriptionally active regions [62]. This 
interaction recruits and stabilizes the mSin3a/HDAC1-2/Sap30 complex on gene promoters 
since ING1 is a stable component of the mSin3a/HDAC1-2/Sap30 complex. This leads to 
histones deacetylation and gene repression. Recently, mutations of ING1b aminoacid residues 
located in the PHD critical for the binding with H3K4Me3 [26,27] has been reported to impair 
the onset of senescence. These mutations modify a specific transcriptome signature after 
senescence induction. This signature is enriched in cytokines and chemokines. Thus, during 
senescence, the recognition of H3K4Me3 by ING1 mediated transcription of genes that 
induce a secretory response in human primary fibroblasts [63]. Consequently, regulation of 
gene transcription through ING1b PHD and the mSin3a/HDAC1-2/Sap30 complex may 
regulate the induction of senescence (Fig.3). Interestingly, ING1a and ING1b regulate histone 
acetylation in a different manner. Overexpression of ING1a decreases acetylation of histone 
H3 whereas overexpression of ING1b does not decrease acetylation of histone 3. ING1b has 
been invoved in histone acetylase and deacetylase complex by interacting with p300 [64] (see 
thereafter) and with the mSin3a/HDAC1-2/Sap30 complex whereas ING1a interacts only with 
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the mSin3a/HDAC1-2/Sap30 complex [28,30]. Thus, Human ING1 isoform differentially 
regulate histones acetylation/deacetylation.  
 Interestingly, in mouse fibroblasts downregulation of ING1b has been described to 
increase the expression of Dgcr8 which encodes for an RNA-binding protein regulating the 
early steps of microRNAs biogenesis. In the absence of ING1b, acetylation on histone H3 and 
histone H4 in the Dgcr8 promoter was described to significantly increase, suggesting that 
ING1b contributes to the transcriptional repression of Dgcr8 by inhibiting histone acetylation 
through the recruitment of deacetylase complexes. This leads to the deregulation of miRNAs 
expression [65]. The deacetylase complex involved in the regulation of ING1b-dependent H3 
and H4 acetylation has not been identified but might be the mSin3a/HDAC1-2/Sap30 
complex. Moreover, deregulation of the microRNA machinery is well characterized in tumors 
[66]. Thus, this is a new pathway by which ING1b downregulation could promote 
tumorigenesis. Moreover, in mouse mammary epithelial cells ING1b has been described to 
negatively control the expression of cyclin B1 and the proto-oncogene DEK, a nucleic acid 
binding protein [67]. The mechanism involved remains unknown but may occur through the 
mSin3a/HDAC1-2/Sap30 complex. In addition, ING1b has also been reported to interact with 
p16 promoter and upregulates p16INGK4a expression in 2BS fibroblasts in a p300-dependent 
manner that lead to induction of cellular senescence [68]. Interestingly, ING1b have been 
reported to interact with p300 acetylase [69] (see thereafter). As a consequence, it could 
promote p300 anchorage on p16 promoter to acetylate this region to activate p16 expression. 
 
 
ING1b regulates p53 activity 
 
 Initially, ING1b overexpression has been described to inhibit cell growth in various 
cell lines [3,70,71]. Then, ING1b was involved in apoptosis caused by serum starvation [72]. 
Interestingly, compared to young fibroblast the level of ING1a mRNA in senescent fibroblast 
is enhanced; whereas, ING1b mRNA is decreased. ING1a has been reported to promote a 
senescent phenotype in human fibroblast whereas ING1b was involved in the induction of 
apoptosis [73,74]. Later, ING1b was also involved in the maintenance of cellular senescence. 
A stable and moderate overexpression of ING1b in young human fibroblasts induces 
senescence in a p53-dependent [63,75]. In addition, coexpression of both ING1b and p53 in 
H1299 cells induces more cell death in response to the adryamycine than these two proteins 
alone, suggesting a close collaboration of these two proteins [76]. Thus, ING1a has been 
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involved in the control of senescence in a p53-dependent manner and ING1b has been 
involved in the regulation of apoptosis and senescence in a p53-dependent manner. 
Interestingly, coexpression of mouse ING1b and ING1c has been reported to activate p53 
transcription more efficiently than mouse ING1b and mouse ING1c alone [76,77]. It is not yet 
clear how mouse ING1c collaborates with mouse ING1b, but, since mouse ING1c is the 
truncated of N-terminus of mouse ING1b, it could be through its C-terminal domain (Fig.S1). 
Thus human and mouse ING1 isoforms have been involved in p53-dependent regulation of 
cell cycle, apoptosis and senescence. 
 In addition, overexpression of human ING1b in HT1299 expressing p53 increases p63 
and p73 expression [76]. Thus, ING1b may also regulate the transcription of two members of 
the p53 protein family which have also tumor suppressor functions [78-80]. Thereafter, 
human ING1b has been described to regulate p53 activity through three different mechanisms. 
Firstly, human ING1b interacts with p300 acetylase to promote p53 acetylation on lysine 382. 
p53 acetylation activates transcription factor functions to regulate p21 and Bax expression to 
induce cell cycle arrest and apoptosis [69,71] (Fig.3). Moreover, human ING1b associates 
which SIRT1 (also known as hSir2) and competitively inhibit SIRT1 association with p53 
[69,81]. SIRT1 is a histone deacetylase described to deacetylate p53. This results in the 
inhibition of p53 deacetylation contributing in the maintenance of p53 activity such as 
activation of transcription of p21 and Bax (Fig.3). Finally, human ING1b may regulate the 
ARF - MDM2 - p53 pathway. ING1b interaction with p53 has been proposed to compete with 
MDM2 - p53 interaction [77]. MDM2 has been described to ubiquitinylate p53 in order to 
mediate its degradation through the proteasome system [82]. More recently, an ubiquitin 
interaction motif (UIM) has been described as an overlapping region on the PBR in the C-
terminal domain of ING1b. Through this region ING1b binds monoubiquitinated p53 to 
prevent its polyubiquitination [83]. Thus, through their interaction, ING1b stabilizes p53 
[77,83]. Then, ARF has been suggested to interact with ING1b to alter its localisation from 
the nucleus to the nucleolus [77,84] (Fig.3). Furthermore, ING1b has been described to 
interact with p53-related proteins p63 and p73 as well as p53 [76]. Consequently, ING1b 
could regulate p63 and p73 activity through similar mechanisms than those involved in p53 
regulation. However, it needs to be investigated. 
 
 
ING1b regulates cell growth and apoptosis independently of p53 
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 ING1b decreases cell proliferation through p53-dependent mechanisms but also 
through p53-independent mechanisms. Human ING1b overexpression in H1299 p53-null cells 
have been reported to decrease cell growth. Moreover, in response to adryanamycine, a DNA 
damaging agent, it enhances the blockage in G2/M checkpoint [76]. In addition, 
downregulation of ING1b in p53 null glioblastoma cells has been reported to increase 
apoptosis in response to cisplatin [37,85]. Consequently ING1b regulates cell growth and 
apoptosis in a p53-independent manner. 
 Moreover, overexpression of human ING1b induces expression of Heat Shock Protein 
70 (HSP70). The N-terminal region of ING1b containing the PIP and the PBD has been 
reported to be required for the induction of HSP70 expression; whereas, the PHD and the 
PBR were not [86]. HSP70 has been reported to inhibit NF-B signalling [87,88]. Thus, by 
regulating HSP70 expression ING1b could indirectly regulate NF-B-dependent cell growth 
and apoptosis [37,86] (Fig.3). 
 Human ING1b interacts with CSIG (Cellular Senescence-Inhibited Gene) through its 
NTS. CSIG is a nucleolar protein which has been involved in the regulation of cellular 
senescence [89]. Human ING1b overexpression increases CSIG protein stability and its 
downregulation decrease CSIG protein level. There interaction and the maintenance of CSIG 
protein level by ING1b is required to activate Bax and apoptosis in response to ultraviolet 
(UV) [90] (Fig.3). 
 
 
ING1 caretaker functions regulate DNA repair in response to UV 
 
 Originally, ING1b expression has been reported to be enhanced in response to UVB in 
mouse keratinocytes and in MMRU melanoma cell line [20,91]. Human ING1b 
overexpression was described to enhance repair of UV-damaged DNA in a p53-dependent 
manner. Interestingly, ING1b binds Growth Arrest and DNA Damage 45 (GADD45) but not 
Xeroderma Pigmentosum A (XPA) and XPB [91] (Fig.3). GADD45 has been described as a 
cofactor to promote DNA demethylation during Nucleotide Excision Repair (NER) without 
any demethylase activity [92]. The mechanism by which ING1b collaborates with GADD45 
to mediate NER remains unknown. In addition, ING1b PHD domain has been shown to play 
an essential role in NER. In fact, truncation of ING1b PHD abrogates DNA repair in response 
to UV-induced damage [93]. We thus could hypothetize that the involvement of ING1b PHD 
in the regulation of DNA repair in response to UV could be through its interaction with the 
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the mSin3a/HDAC1-2/Sap30 complex [28,30]. Interestingly, ING1b has then been shown to 
regulate H4 acetylation to promote global chromatin relaxation to allow XPA recruitment 
[94]. A more recent study has described that downregulation of ING1b decreases PCNA 
monoubioquitination and sensitizes cells in response to UV during S phase [95]. Defect of 
ING1b results in chromatin break and sister chromatin exchange in response to UV. The E3 
ubiquitin ligase Rad18 is known to mediate PCNA monoubioquitination in response to UV to 
ensure lesion bypass and error prone DNA replication [96,97]. In fact, ING1b is required for 
the loading of Rad18 on chromatin at replication sites upon replication stress to mediate 
PCNA monoubiquitination. A strong regulation of H3 and H4 acetylation by ING1b has been 
reported to support Rad18-dependent PCNA ubiquitinylation [95] (Fig.3). Therefore, ING1b 
facilitates NER and regulation of DNA replication upon UV stress through regulation of 
histone acetylation. Two mechanisms of such regulation could be considered. Firstly, ING1b 
through its involvement in the mSin3a/HDAC1-2/Sap30 complex could regulate histone 
acetylation and thus allow the access of GADD45 and Rad18 to the chromatin. The second 
hypothesis is through ING1b interaction with p300. ING1b has been described to interact with 
p300 and its overexpression has been reported to alter PCNA - p300 interaction in response to 
UV [64]. By regulating PCNA-p300 interaction, ING1b could also regulate H4 acetylation in 
response to UV-induced DNA damage to facilitate GADD45 and Rad18 accessibility to the 
chromatin but it needs to be experimentally confirmed. 
 Interestingly, ING1b interacts also with PCNA through its PIP domain. Mutation in 
the PIP domain decreases apoptosis in response to UV. Thus, binding between ING1b and 
PCNA is necessary to mediate apoptosis in response to UV. Moreover, this interaction 
strongly increases in response to UV and could compete with other PIP containing proteins 
such as p21 known to regulate the switch from DNA replication to DNA repair. 
Consequently, ING1b-PCNA interaction was proposed to regulate the switch from DNA 
replication to DNA repair by altering the composition of the replication protein complex to 
promote apoptosis [34]. In addition, p15PAF associates with both PCNA and ING1b in 
response to UV. p15PAF possesses a PIP domain and has been described to compete with p21 
for PCNA binding when overexpressed [98]. Since PCNA is organized as a ring-like 
homotrimer, it contains three binding sites for proteins having a PIP motif [99,100]. It has 
been proposed that the association of PCNA with ING1b together with p15PAF could more 
efficiently compete with the binding of PCNA and p21 [101] (Fig.3). 
 To conclude, ING1b regulates DNA repair in response to UV through its interaction 
with GADD45 and PCNA and through the regulation of histone acetylation. How ING1b 
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regulates histone acetylation in response to UV remains unsolved but it is clear that ING1b 
promotes the remodelling of the chromatin structure to provide accessibility of DNA repair 
factors. Thus, it also interacts with some factors to promote their recruitment and/or their 
function. 
 
 
ING2 gatekeeper functions regulate cell cycle, senescence and apoptosis 
 
 Initially, ING2a has been shown to negatively regulate cell proliferation because it 
enhances p53 transcription [4]. Subsequently, through its interactions with HDACs and with 
acetylases, ING2a has been involved in the regulation of genes involved in cell cycle control, 
senescence and apoptosis. 
 
 
ING2 controls gene transcription 
 
 ING2a has been shown to interact directly with histones to regulate gene transcription. 
ING2a PHD is necessary and sufficient for a strong interaction between ING2a and 
H3K4Me3 and a weaker interaction with histone mono or dimethylated on lysine 4 [27]. 
Trimethylated histone mark is mainly found in transcriptionally active regions [62]. This 
interaction recruits and stabilizes the mSin3a/HDAC1-2/Sap30 complex on gene promoters 
since ING2a is a stable component of the mSin3a/HDAC1-2/Sap30 complex. This leads to 
histones deacetylation and gene repression [26,27,102-104] (Fig.3). Interestingly, ING2 male 
KO mice germinal cells show an impaired expression of HDAC1 during spermatocyte 
differentiation. It results in the accumulation of acetylated histones associated with meiosis 
arrest [17]. This highlights the significance of ING2a in histones acetylation/deacetylation 
process to regulate gene expression. ING2a involvement in chromatin remodeling through the 
mSin3a/HDAC1-2/Sap30 complex could thus change the accessibility of transcription factors 
to the chromatin or could allow the accessibility to other chromatin remodeling factors to 
modify transcription factors expression and/or recruitment. Indeed, epigenetic changes have 
been described to contribute to carcinogenesis [105]. Thus, ING2 loss, as it occurs in tumors, 
could trigger epigenetic modifications participating in the tumorigenesis process. 
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 Through this mechanism ING2a regulates p21 transcription since ING2a is critical for 
the binding of the mSin3a/HDAC1-2/Sap30 complex to the p21 promoter. Indeed, the use of 
suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, causes the 
dissociation of ING2 from the mSin3a/HDAC1-2/Sap30 complex resulting in the disruption 
of the binding of the mSin3a complex from the p21 promoter [103]. Moreover, ING2a 
sumoylation by Small Ubiquitin-like MOdifier 1 (SUMO1) on Lysine 195 has been described 
to enhance the interaction between ING2a and mSin3a [106]. Effects of SAHA on ING2a 
sumoylation need to be explored to clarify whether ING2 disruption is not a consequence of a 
modification of its sumoylation status. It is also possible that ING2 sumoylation regulates 
other interactions between INGa and other partners to regulate other ING2a functions. Indeed, 
ING2 sumoylation site is located in a potential Phosphorylation Dependent Sumoylation 
Motif (PDSM) [106]. Thus ING2a could be sumoylated on Lysine 195 in a manner dependent 
on its phosphorylation on Serine 201. Interestingly, the same PDSM motif is also present on 
ING1. In this case the serine residue has been shown to be phosphorylated in order to regulate 
ING1 export from the nucleus. Interestingly, it results in a decrease of p21 expression [32]. 
Therefore, since ING2a sumoylation has been shown to regulate its interaction with the 
mSin3a/HDAC1-2/Sap30 complex, ING2a potential phosphorylation on Serine 201 could 
also regulate its interaction with mSin3a and consequently p21 expression. An independent 
study has shown that ING2a downregulation induces the decrease of p21 expression and thus 
accelerates the progression of cells from G1 to S phase. Binding of ING2a to H3K4Me3 has 
been proposed as a mechanism to regulate the G1/S transition by regulating p21 expression. 
Indeed, downregulation of WD40-repeated protein WDR5, which recognizes lysine 4 of H3 
to facilitate methylation of lysine 4 of H3 or simultaneous downregulation of WDR5 and 
ING2a accelerates cell progression from G1 to S phase in the same manner than ING2 
downregulation [107] (Fig.3).  
 ING2a regulates cell proliferation also by regulating TGF- dependent transcription. 
TGF- regulates homeostasis and has tumor suppressor properties such as inhibition of 
proliferation, vessels formation and regulation of apoptosis. Dysfunction of TGF- signaling 
has been implicated in cancer development [108]. Thus, in response to TGF- signaling, 
ING2a binds SnoN (Ski-like oncogene), a Smad-interacting transcriptional modulator, 
through its PHD domain. SnoN binds ING2a to form a complex that associates ING2, SnoN 
and Smad2. Consequently, Smad2 enhances TGF--dependent transcription that contributes 
to the inhibition of cell proliferation [109] (Fig.3). Interaction of ING2a PHD with SnoN 
could compete with ING2 PHD interaction with the mSin3a/HDAC1-2/Sap30 complex. Thus 
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HDAC1-2 would not be recruited to TGF--dependent gene promoters and would not be able 
to acetylate chromatin to inhibit their transcription. Thus, ING2 loss, as it occurs in human 
tumors, could allow cancer cells to escape from Smad2-TGF- dependent regulations. 
 To summarize, through the regulation of chromatin remodelling on promoter of genes 
such as p21 and TGFβ-responding genes, ING2a regulates expression of genes involved in 
cell cycle control. 
 
 
ING2 regulates acetylation of p53 and p73 to inhibit cell growth 
 
 ING2a is involved in signalling pathways that regulate other gatekeeper TSG. Initially, 
ING2a was characterized as being involved in the p53-dependent pathways [4]. ING2 
overexpression in young fibroblast arrests cell in G1 and induces senescence with a phenotype 
similar to p53 overexpression while siRNA targeting ING2 decreases senescence. 
Mechanistically, ING2a interacts with the p300 acetyltransferase to enhance p53 acetylation 
on lysine 382 to increase transcription of p53 target genes particularly p21 and Bax to control 
cell cycle arrest, senescence and apoptosis [4,110] (Fig.3). Moreover, a mechanism involving 
PtdInsP has been reported to regulate ING2-p53-dependent pathway. ING2a has been 
described as a nuclear receptor to PtdInsP since it interacts with PtdIns(5)P through its PBR 
region [25,111]. In response to exogenous stresses, the p38 kinase pathway is activated to 
regulate phosphorylation of PtdIns(5)P resulting in an increase of nuclear PtdIns(5)P. p38 has 
tumor suppressor properties since it has been described to regulate cell proliferation and to 
negatively regulate cell cycle progression of both G1/S and G2/M checkpoints [12]. Nuclear 
PtdIns(5)P increase induces ING2a accumulation to the chromatinThis interaction modulates 
the ability of ING2a to regulate p53 acetylation. It results in p21 expression and cell death 
activation [25,112] (Fig.3). Interestingly, ING1b has also been shown to interact with 
PtdInstP(5)P through its PIP [25]. Thus, as ING2a, ING1b through its interaction with 
PtdInstP(5)P could have an accumulation to the chromatin and then modulate the acetylation 
of p53. Moreover, ING2a has been also described to be able to bind chemically synthesized 
analogues of the PtdInstP(5)P [113,114]. Interestingly, a simultaneous reintroduction of ING2 
and PtdInstP(5)P or PtdInstP(5)P analogues in HT1080 cells enhances cell death in response 
to DNA Damage [114]. In the context of anticancer therapies, the concomitant reintroduction 
of ING2 toghether with PtdInstP(5)P or PtdInstP(5)P analogues could be thus a strategy to be 
considered (see discussion). 
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 p73 belongs to the p53 protein family and has tumor suppressor properties. It 
regulates transcription of genes involved in cell cycle arrest and in apoptosis such as p21, 
PUMA and Bax [78]. The p73 protein is activated in response to N-methyl-N’-nitro-N-
nitrosoguanidine (MNNG), a genotoxic agent. A study reported that in response to MNNG 
treatments, in cell lines not mutated for p53, ING2a is upregulated in a dose and time 
dependent manner. In response to this genotoxic agent, ING2a is not required for p53 
induction and acetylation but it is required for the induction and the acetylation of p73 to 
promote cell death. It remains unclear through which acetylase ING2a facilitates p73 
acetylation. Since p73 has been shown to be acetylated by p300 to modulate cell death, and 
since ING2a has been reported to interact with p300 to mediate p53 acetylation [110], p300 is 
a good candidate which will need to be tested [115,116]. 
 To conclude, ING2a regulates p53 and p73 acetylation and as a consequence 
regulates transcription of genes involved in cell cycle arrest, apoptosis or senescence. 
Interestingly, p300 has also been describes as a HAT which can acetylate H2A, H2B, H3 and 
H4 [117,118]. Thus, ING2a could also regulate, through its binding with H3K4Me3, the 
anchorage of the p300 to allow acetylation of specific genomic area to regulate gene 
transcription. A competition with the mSin3a/HDAC1-2/Sap30 complex in response to 
different exogenous or endogenous signals or stresses could thus occur. 
 
 
ING2 caretaker functions maintain genome stability 
 
 Two set of studies have shown the involvement of ING2 in DNA replication and NER 
suggesting that it may also act as a caretaker TSG. 
 
 
ING2 regulates DNA replication 
 
 ING2a downregulation experiments have shown an impaired normal DNA synthesis 
because of a reduced replication speed during the elongation process. Indeed, ING2 interacts, 
through its NCR domain, with Proliferating Cell Nuclear Antigen (PCNA) which acts during 
elongation by regulating DNA polymerases processivity. ING2a regulates its recruitment to 
the chromatin and is thus necessary for the optimal progression of DNA replication forks 
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[119] (Fig.3). How ING2a regulates PCNA recruitment to the chromatin remains unsolved. 
One hypothesis is that ING2a could regulate PCNA activity by regulating its post-
translational modifications. Interestingly, p300 has been shown to bind PCNA [120]. Thus, as 
observed for the activation of the transcription factors p53 and p73, ING2a could allow the 
acetylation of PCNA on replication forks, may be through p300 acetylase, to enhance PCNA 
activity. In addition, a model has been proposed where ING2, ING4 and ING5 could be 
involved at different steps of the normal replication process [121]. Indeed, since both ING4 
and ING5 have been described to be part of HAT complexes, they could allow histone 
acetylation around replication origins. Then, the relaxed chromatin state would allow the 
recruitment of the MCM helicase complex which interacts to ING5 [104]. Afterwards, thanks 
to its interaction with ING2a, PCNA would regulate the polymerase processivity [119,121]. 
ING2 which interacts with p300 acetylase could also regulate local acetylation around the 
replication forks. Moreover, depletion of ING2a results in a high frequency of genome 
endoreplication, sister chromatid exchange and accumulation of DNA double strand breaks 
[119] (Fig.3). Consequently, loss or downregulation of ING2, as it occurs in human tumors, 
slows down the replication process, contributing to genomic instability which could 
contribute to tumorigenesis. 
 
 
ING2 is involved in NER in response to UV 
 
 ING2a plays an important role in DNA repair in response to UV. It was firstly shown 
that ING2 overexpression increases NER in response to UV in a p53 dependent manner; 
whereas, downregulation of ING2a decreases NER efficiency in response to UV. However, 
ING2 does not colocalize with UV-induced DNA damage. Instead, ING2a is required for H4 
acetylation and chromatin relaxation in response to UV to facilitate the recruitment of XPA to 
photolesions [122]. More specifically, ING2a LZL domain has been shown to be critical for 
this process while its PHD motif is dispensable. The deletion of ING2a LZL decreases NER 
efficiency and apoptosis induced by UV-damage. In response to UV-DNA damage, ING2a 
LZL domain binds p53 and mediates the interaction between p53 and p300 acetylase in order 
to stabilize them to the chromatin [122,123]. The ING2a LZL domain is also required for H4 
hyperacetylation and chromatin relaxation to promote NER [123] (Fig.3). Moreover, the 
association between p53 and p300 has also been shown to be involved in H3 histone 
acetylation [124]. Thus, by mediating the association between p53 and p300 in response to 
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UV, ING2 could facilitate the anchorage of p300 on specific genomic sites to support H3 and 
H4 hyperacetylation to promote the accessibility of NER factors to the chromatin. Moreover, 
PCNA is involved in several steps of NER DNA synthesis. Interestingly, Hasan and coll. have 
reported that PCNA interacts with p300 to promote DNA synthesis after UV irradiation [120]. 
Because ING2 regulates PCNA recruitment to the chromatin during the replication process 
[119], it could also regulate PCNA interaction with p300 and its recruitment for the NER. 
Additional experiments will be required to complete these results. In fact, these results have 
mostly been carried out using ING2a overexpression strategies which is known to have 
supraphysiological effects. For example, ING1b and ING2a were firstly described to be 
involved in p53-dependent apoptosis whereas siRNAs or knockout studies have shown that 
both ING1b and ING2a are also involved in p53-independent apoptosis. However, since the 
expression of ING2 is lost in melanoma [58], it would be interesting to analyse at which step 
of skin cancer development ING2 has been lost to determine if a loss of its NER function has 
been playing any role in the tumorgenesis process. 
 
 
Crosstalk between ING1 and ING2 tumor suppressor functions 
 
 ING1 and ING2 are two tumor suppressor that have gatekeeper and caretaker TSG 
functions. Both ING1b and ING2a are stable components of the mSin3a/HDAC1-2/Sap30 
complex and thus both regulate gene transcription. Since ING1b and ING2a do not 
coprecipitate together, they are exclusive components of the mSin3a/HDAC1-2/Sap30 
complex. The reason that explains why both are involved in these complexes remains 
unknown. Depending of the cellular context, they could have complementation effects to 
regulate gene expression such as p21 expression. They also could target different promoters to 
regulate the expression of different genes. Interestingly, in Yeast, Pho23, the ING yeast 
related to ING1 and ING2 in Saccharomyces cerevisiae [8], has also been purified as a stable 
component of Rpd3/HDAC complex. Rpd3 is the catalytic components of the yeast 
Sin3/HDAC complex [104,125]. Consequently, the association of ING1 and ING2 with the 
Sin3/HDAC complex is conserved from Yeast to Human suggesting that this function has 
been critical for epigenetic regulation throughout the evolution. 
 Interestingly, both ING1b and ING2a regulate p53. First, ING1b and ING2a both 
regulate acetylation of p53 to regulate cell cycle, apoptosis and senescence [63,75,110,126] 
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(Fig.3). Since ING2a regulates p73 acetylation [127] and ING1b has been described to 
interact with p73 [76] it is possible that ING1b regulates also p73 acetylation. ING1b has also 
its own functions to mediate p53 activity since the involvement of ING2 in the ARF - MDM2 
- p53 pathway has never been demonstrated [77,83]. In addition, by interacting with the 
acetylase SIRT1, ING1b inhibit SIRT1 – p53 interaction resulting in the maintenance of p53 
acetylation [81,69] (Fig.3). Interestingly ING2a has also been described to bind SIRT1 [81]. It 
remains thus possible that ING2a may, as ING1b, inhibit SIRT1 association with p53. 
 By controlling acetylation of histones and by regulating transcription factors activity 
or protein expression level, ING1b and ING2a regulate transcription of genes involved in cell 
cycle arrest, apoptosis and senescence. Consequently, ING1b and ING2a act as gatekeeper 
TSGs. Their loss may confer growth advantage because of the loss of transcription control of 
these genes. Thus, cells lacking ING1b or ING2a could bypass cell cycle checkpoint controls, 
proliferate and be positively selected (Fig.4). 
 Interestingly, the two close homologs ING1b and ING2a are both involved in the 
regulation of DNA replication through two independent mechanisms. Initially, ING1 
expression was described to be cell cycle-dependent. Its expression is increased from G1 to S 
phase and then decreases in G2 phase [126]. Later, ING2a expression was shown to also be 
dependent of the cell cycle, ING2a expression is enhanced in S phase reaching a maximum in 
G2 phase [119], suggesting an involvement of both ING1b and ING2a in the S phase. 
Actually, ING2a has been described to be necessary to regulate DNA replication 
independently of exogenous stress [119]; whereas, ING1b mediates replication in response to 
UV [95]. Consequently, ING1b and ING2a have specific functions involving them in 
replication. However, why ING2a but not ING1b is involved in the progression of the normal 
DNA replication forks remains unknown. One hypothesis would be that because ING2a does 
not possess a PIP domain, it does not interfere with other PIP proteins in response to DNA 
damage and consequently it does not regulate the switch from DNA replication to DNA 
repair. However, a recent nuclear magnetic resonance study demonstrated that ING1b PIP 
binds PCNA with a very low affinity, probably because ING1b PIP motif lacks a second 
aromatic residue usually presents in the canonical PIP motif [128]. Strikingly, it is ING2a 
NCR domain, also found on ING1b, which has been involved in the interaction between 
ING2 and PCNA [119]. Since interaction of ING1b PIP domain with PCNA has been 
demonstrated using only ING1 PIP mutant [34] and since this interaction has a very low 
affinity [128] (Fig.3), it would be of interest to test whether the ING1b NCR domain could 
mediate or facilitate the interaction with PCNA. It remains also possible that the interaction 
Guérillon et al., 2013 
24 
between ING1b and PCNA is promoted by post-translational modifications or by other PCNA 
interacting proteins. 
 In addition, ING1b and ING2a have both been involved in the regulation of NER 
through regulation of histone acetylation. ING1b and ING2a could either collaborate or act 
independently to regulate NER but it remains to be experimentally verified. Moreover, 
because both are also involved in the mSin3a/HDAC1-2/Sap30 complex in response to 
exogenous stress, it would be interesting to understand how the switch toward one or the other 
complexes is carried out and how the ING1b and ING2a pools are distributed to regulate 
histone acetylation and deacetylation. 
 Altogether, these studies involve ING1b and ING2a in the regulation of chromatin 
acetylation to promote a favourable chromatin state that allows the access of DNA replication 
or DNA repair proteins to DNA thus contributing to genome stability maintenance. 
Deregulation of DNA repair and DNA replication are functions which are closely associated 
with early steps of tumorigenesis [1,129]. Early loss of ING1b and ING2a expression, as it 
occurs in human tumors may contribute in an enhancement of genome instability and could 
initiate the tumorigenesis process. Then, the accumulation of later events such as passenger 
mutations and DNA modifications will promote the development and the progression of 
cancer (Fig.4). 
 
 
Conclusions and future directions 
 
 Originally ING1 was identified with the aim to identify new tumor suppressor genes 
[3]. Then, studies conducted on ING1b about its status in tumors and its functions have fully 
established the status of ING1b as a tumor suppressor [13,37]. Later, ING2 has been identified 
thanks to a high homology to the tumor suppressor gene ING1. Subsequently ING2 was 
characterized as a “candidate” TSG. Since, studies have demonstrated that, both ING1b and 
ING2a are frequently lost in human tumors and that both knockout mice models 
spontaneously develop B-cell lymphomas and soft-tissue sarcomas respectively [13-17]. In 
addition, the better understanding of ING1b and ING2a biological functions has contributed 
to confirm their TSG status. Interestingly, a study involving ING1 in a mechanism is most of 
the time also true for ING2. Indeed, ING1b and ING2a which regulates cell cycle, apoptosis 
and senescence, have thus been defined as a gatekeeper TSG (or type 2). Recent studies have 
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also shown ING1b and ING2a involvement in the maintenance of genome stability by 
regulation of both DNA replication and NER. Accordingly, as its close homolog ING1b, 
ING2a has also been defined as a caretaker TSG (or type 2).  
 Consequently, as they are TSGs, the loss of ING1b or ING2a in human tumors could 
be involved in the tumorigenesis process. On one hand, loss of ING1b and ING2a caretaker 
functions could enhance genome instability that could initiate tumorigenesis, while loss of 
ING1b and ING2a gatekeeper functions would allow cells to bypass cell cycle checkpoint and 
apoptosis to be positively selected (Fig.4). However, how and why ING1b and ING2a are lost 
in tumors remains unclear. We still do not know which mechanism that initiates ING1 and 
ING2 loss. Genetic and epigenetic susceptibility as well as environmental factors are probably 
involved in this process.  
 Recent studies have allowed a better understanding of fundamental cellular and 
molecular mechanisms in which ING1b and ING2a are involved such as cell cycle regulation 
and DNA repair. A better understanding of their protein structure has allowed the association 
of their protein domains with their functions. However, the specificity of these proteins has 
not yet been fully established, e.g. we still do not know the usefulness of the NCR domain 
present only on ING proteins. No ING1b or ING2a protein enzymatic activity has been 
identified. Instead, ING1b and ING2a could be factors that promote acetylation or 
deacetylation of histones and transcription factors to activate these proteins and/or to allow a 
favourable chromatin state to regulate gene transcription or DNA replication and DNA repair. 
Moreover, we still do not know how ING1b and ING2a are involved in different complexes. 
It has not yet been established whether ING1b or ING2a could be free or only in complex. 
Further, it is not known how ING1b or ING2a exchange between protein complexes is 
processed. Post-translational modifications such as phosphorylation or sumoylation could 
regulate either this exchange or their targeting towards a protein complex rather than another.  
 Since ING1b and ING2a are TSGs, they are interesting proteins to look at in the 
context of anticancer therapies. First of all, ING1b and ING2a could be used as a biomarker 
for cancer diagnosis. Establishing ING1 and ING2 status in tumours could also be important 
for the therapeutic choices. It could allow the identification of defective signalling pathways 
in tumor cells which would be targets of interest for treatment. Interestingly, a recent study 
has revealed that simultaneous overexpression of ING1b and treatment with 5-azacytidine 
synergize to block the growth of breast cancer cell lines and mouse tumor xenografts. ING1b 
could be used of a therapeutic agent since it enhances the efficacy of 5-azacytidine [130]. 
Moreover, since ING1b and ING2a are lost or downregulated at the RNA level in human 
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cancers [13], an interesting strategy would be to re-express ING1 or ING2 or to stabilize their 
protein level. ING2a has already been described to bind PtdInstP(5)P analogues [113,114]. 
Since, their concomitant reintroduction into HT1080 cells have been reported to enhance cell 
death in response to DNA damage [114], a possible strategy would be to simultaneously 
reintroduce ING2 and PtdInstP(5)P analogues in tumor cells to enhance tumor cells death 
[112,114].  
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Legend to Figures 
 
Figure 1: Structure of Human ING1 and ING2 genes, mRNAs and proteins. 
A. ING1 human gene. E1c, E1d, E1a, E1b, E1balt, E2 are respectively Exon 1c, Exon 1d, 
Exon 1a, Exon 1b, Exon 1balt and Exon 2. B. ING1b human mRNA. C. ING1b human 
protein. ING1b protein contains a PIP and a PBD in its N-terminal part, a NCR and a NLS in 
its central region and a PHD and a PBR in its C-terminal part. This figure of ING1 is 
simplified, the full version has already been published [13] and can also been found in Fig.S1. 
D. ING2 human gene. E1, E2 are respectively Exon 1 and Exon 2. Exon 1a promoter contains 
two p53 Binding Site (p53BS) and a NF-B Responsive Element (NRE). E. ING2 human 
mRNAs. F. ING2 human proteins. ING2a contains a LZL in its C-terminal part. ING2a, 
ING2b possess a NCR and a NLS with three NTS, a PHD zinc finger motif and a PBR. 
ING2a and ING2b are both represented in this figure since ING2b has never been included in 
a scheme describing ING2 proteins since its identification. On genes and mRNAs, none 
coding regions are in yellow and coding region are represented in purple. Each mRNA variant 
is represented with its name on the left and its Genebank accession number on the right. Each 
protein is represented with its characterized domains with its name on the right and with its 
molecular weight, and its Genebank accession number on the left. 
 
Figure 2: Sequences alignment of human ING1b and ING2 genes and proteins. 
A. cDNA sequences alignment of human ING1b and of human ING2a and ING2b. B. Amino 
acid sequences alignment of human ING1b and ING2a and ING2b. All Alignments were 
carried out using CLUSTAL 2.1 multiple sequence alignment software. Asterisks mean a 
perfect alignment between each sequence. The PIP is colored in pinked purple; the LZL is 
colored in green; the PBD is colored in blue; the NCR is colored in purple; the NLS is 
highlighted in blue; the three NTS are colored in blue; The REASP aminoacid motif is 
colored in pink; the PHD is colored in red and the PBR is colored in orange. 
 
Figure 3: ING1 and ING2 gatekeeper and caretaker TSG functions.  
Human ING1b and ING2a are represented with their interacting proteins to modulate their 
gatekeeper and caretaker functions. A. ING1b gatekeeper functions. ING1b regulate p53 
activity through regulation of its acetylation status by interacting with p300 and SIRT1. 
ING1b regulates also p53 protein stability by inhibiting p53 MDM2-dependent degradation. 
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In response to genotoxic stress ING1b interacts with the the mSin3a/HDAC1-2/Sap30 
complex through its NCR and with H3K4Me3 through its PHD to regulate gene transcription. 
ING1b caretaker functions. In response to UV ING1b binds GADD45 to promote NER. It 
also interacts with PCNA to facilitate its monoubiquitinylation. ING1b interaction with 
PCNA may also promote the switch from DNA replication to DNA repair in response to UV. 
B. ING2a gatekeeper functions. Under stress conditions, ING2a binds the PIP5 through its 
PBR to promote its accumulation to the chromatin. Then, ING2a interacts through its LZL 
with the acetylase p300 to support p53 acetylation and the transcription of genes involved in 
cell cycle arrest, apoptosis and senescence. Stress induced by MNNG treatment regulates 
ING2a to induce p73 acetylation in order to activate transcription of genes involved in 
apoptosis. Genotoxic stress regulates ING2a to interact with the mSin3a/HDAC1-2/Sap30 
complex and with H3K4Me3 through its PHD to regulate gene transcription. In response to 
TGF- signaling, ING2a binds SnoN through its PHD to allow the interaction between SnoN 
and Smad2 in order to inhibit TGF- dependent transcription resulting in inhibition of cell 
proliferation. ING2a caretaker functions. ING2a LZL is involved in NER in answer to UV 
stress. ING2a can also interact with PCNA to ensure the normal progression of the replication 
fork and to maintain genome stability. When the domain of interaction with ING1b or ING2a 
is unknown the protein is represented below the protein scheme. Me and Ac mean 
respectively methyl group and acetyl group. 
 
Figure 4: ING1 and ING2 tumor suppressor functions.  
In normal cell growth or stressed conditions ING1 and ING2 regulate DNA replication and/or 
DNA repair to maintain genome integrity. Exogenous or physiological stress activates ING1 
and ING2 to regulate cell proliferation through the activation of cell cycle arrest, senescence 
or apoptosis to prevent tumor transformation. Consequently, ING1 or ING2 loss, as it occurs 
in human tumors triggers loss of its functions. Thus, ING2 loss contributes to disregulation of 
cell growth and to enhance genome instability. Consequently, ING1 and ING2 act as tumor 
suppressor genes of type I or “caretakers” as well as type II or “gatekeepers” to prevent 
tumorigenesis.  
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Legend to Supplemental 
 
Figure S1: Structure of Human ING1, mouse ING1 and ING2 genes, mRNAs and 
proteins. 
A. ING1 human gene. E1c, E1d, E1a, E1b, E1balt, E2 are respectively Exon 1c, Exon 1d, 
Exon 1a, Exon 1b, Exon 1balt and Exon 2. Exons E1d and E1balt of ING1v2 and ING1v5 are 
represented in orange. They both code for the same protein ING1c (ING1v2/v5) as their ATG 
on E2 is the same. B. ING1 human mRNAs. C. ING1b human protein. All ING1 protein 
isoforms contain a NCR and a NLS in their central region and a PHD and a PBR in their C-
terminal part. ING1b is also composed of a PIP and a PBD in its N-terminal part. D. ING1 
mouse gene. E1a, E1b, E2 are respectively Exon 1a, 1b, 1c and Exon 2. E. ING1 mouse 
mRNAs. F. ING1 mouse proteins. The three mouse ING1 isoforms possess a NCR, a NLS, a 
PHD and a PBR . In addition, mouse ING1b contains a PIP and a PBD in its N-terminal 
domain. G. ING2 mouse gene. E1a, E1b, E2 are respectively Exon 1a, 1b and Exon 2. H. 
ING2 mouse mRNAs. I. ING2 mouse proteins. ING2a contains a LZL in its C terminal part. 
ING2a possesses a NCR and ING2b is truncated of a part of the NCR domain. Both ING2a 
and ING2b are composed of a NLS containing three NTS, a PHD zinc finger motif and a 
PBR. On genes and mRNAs, none coding regions are in yellow and coding region are 
represented in purple. Each mRNA variant is represented with its name on the left and its 
Genebank accession number on the right. Each protein is represented with its characterized 
domains with its name on the right and with its molecular weight, and its Genebank accession 
number on the left. 
 
Figure S2: Sequences comparison between human and mouse ING1b or ING2 cDNAs 
and proteins. 
A. Human ING1b and mouse ING1 cDNA sequences alignment. B. Human ING1b and 
mouse ING1 protein sequences alignment. C. Human and mouse ING2 cDNA sequences 
alignment. D. Human and mouse ING2a and ING2b proteins alignment. For all alignments, 
the PIP is colored in pinked purple; the LZL amino acid sequence is colored in green the PBD 
is colored in blue; the NCR is colored in purple; the NLS is highlighted in blue; the three NTS 
are colored in blue; the REASP aminoacid motif is colored in pink; the PHD is colored in red; 
the PBR is colored in orange. All alignments were carried out using CLUSTAL 2.1 multiple 
sequence alignment software. 
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